Antibodies blocking PlGF or VEGF interactions with the NRP1 receptor mediate anti-proliferative effects.

ABSTRACT: Antibodies blocking the function of vascular endothelial growth factor A (VEGFA) remain a promising therapeutic strategy, especially when combined with check-point inhibitors, but their efficacy is limited by tumor resistance. This can occur via multiple mechanisms, including upregulation of placental growth factor 2 (PlGF-2), an alternative ligand for VEGF receptor 1 (VEGFR1) and neuropilin receptor 1 (NRP1). Activity of both growth factors is mediated by interactions with multiple receptors and extra-cellular matrix components, which complicates efforts to understand their contributions to cancer progression. To complement existing antibodies, we discovered those blocking interactions between PlGF-2 or VEGFA and their shared NRP1 receptor in the presence of heparin. Limiting angiogenesis

SUBMITTER: Blackman SA 

PROVIDER: S-EPMC12645800 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature